Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Drug Safety

The legacy of general health and science information has long provided a foundational framework for understanding how pharmaceutical interventions interact with human physiology. Within this broad context, public health communications have historically emphasized the benefits of medications for chronic conditions, while also acknowledging the potential for adverse effects. This balanced perspective has been essential for informed patient decision-making and clinical oversight. Transitioning from this general health paradigm, a more focused inquiry emerges regarding specific drug-safety profiles. Bisphosphonates, such as Fosamax, have been widely prescribed for bone density management, yet clinical observations have identified a rare but serious condition: osteonecrosis of the jaw (ONJ). The shift in focus from general health education to a targeted risk assessment involves examining the causal relationship between Fosamax exposure and ONJ development. This pivot requires a rigorous review of clinical evidence, moving beyond broad health literacy to scrutinize patient-specific factors, including duration of therapy and dental health status.

Bridging to Clinical Evidence: Fosamax and ONJ

The occupational exposure concern, while not directly applicable to patients, parallels this analytical shift: it demands a transition from population-level health information to individualized risk evaluation, where the exposure agent—here, a pharmaceutical—is assessed for its potential to cause specific tissue injury under defined conditions. This transition underscores the need for precise clinical evidence review to establish causation. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ).

Clinical Presentation and Diagnosis of ONJ

ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but typically associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation includes pain, swelling, infection, and exposed bone that fails to heal over weeks to months. Diagnosis is based on clinical examination and imaging, with histopathology confirming necrotic bone. The condition can lead to significant morbidity, including chronic pain, difficulty eating, and secondary infections.

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates inhibit osteoclast-mediated bone resorption, which is beneficial for increasing bone density but can also suppress normal bone turnover. In the jawbone, which has high remodeling rates due to constant mechanical stress and dental procedures, this suppression may impair the repair of microdamage and the healing response to infections or trauma. The current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structural and cellular properties of the jawbone make it particularly vulnerable to bisphosphonate-induced toxicity.

Time to Onset and Clinical Trial Data

The time to onset of ONJ symptoms after starting Fosamax varies widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear causal timeline. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be detected in typical trial populations. However, post-marketing surveillance has confirmed the association. Most patients experience relief of symptoms after stopping the drug, but a subset has recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), supporting a causal relationship.

Risk Factors and Prevention

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of precise duration guidance may leave some patients at risk for prolonged exposure.

Causation Considerations for Affected Patients

For affected patients, causation-related considerations are complex. The variable time to onset and the presence of other risk factors (e.g., dental procedures, cancer, corticosteroids) make it difficult to attribute ONJ solely to Fosamax in individual cases. The recurrence of symptoms upon rechallenge with bisphosphonates provides strong evidence of a causal link, but this is not always observed. Patients who develop ONJ while on Fosamax should be evaluated for other contributing factors, and the drug should be discontinued if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm can range from days to months, and in some cases, ONJ may occur after years of use, particularly in patients with additional risk factors.

Summary and Clinical Implications

In summary, Fosamax is associated with an increased risk of ONJ, particularly in patients with dental risk factors or prolonged use. The prescribing information includes warnings, but the rare nature of the event and the multifactorial etiology complicate risk assessment. Patients and clinicians should weigh the benefits of fracture prevention against the potential for ONJ, especially in those with pre-existing dental conditions or who require invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate) is a bisphosphonate that has been linked to ONJ, as it suppresses bone turnover, impairing healing in the jawbone. The prescribing information includes warnings about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and pre-existing dental disease. The risk may increase with longer duration of Fosamax use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is the causal link between Fosamax and ONJ established in clinical evidence?

Causal evidence includes post-marketing surveillance showing ONJ in patients on bisphosphonates, symptom relief upon discontinuation, and recurrence upon rechallenge. However, the variable time to onset and presence of other risk factors complicate individual causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.